

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 3)\***

**Bolt Biotherapeutics, Inc.**

---

**(Name of Issuer)**

**Common Stock, \$0.00001 par value**

---

**(Title of Class of Securities)**

**097702203**

---

**(CUSIP Number)**

**Robert Hopfner**  
**Pivotal bioVenture Partners Fund I UGP, 501 2nd Street, Suite 200**  
**San Francisco, CA, 94107**  
**(415) 697-1002**

**Louis Rambo**  
**Proskauer Rose, LLP, 1001 Pennsylvania Avenue NW, Suite 600**  
**Washington, DC, 20004-2533**  
**(202) 416-6800**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**02/05/2026**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No. 097702203**

1 Name of reporting person  
Nan Fung Group Holdings Limited  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 VIRGIN ISLANDS, BRITISH

7 Sole Voting Power  
Number of Shares Beneficially Owned by Each Reporting Person With: 0.00  
8 Shared Voting Power  
128,119.00  
9 Sole Dispositive Power  
0.00  
10 Shared Dispositive Power  
128,119.00

11 Aggregate amount beneficially owned by each reporting person  
128,119.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 Percent of class represented by amount in Row (11)  
6.7 %

14 Type of Reporting Person (See Instructions)  
CO

**SCHEDULE 13D**

**CUSIP No.** 097702203

1 Name of reporting person  
NF Investment Holdings Limited  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

6 VIRGIN ISLANDS, BRITISH

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person 8 0.00

9 Shared Voting Power

10 128,119.00

11 Sole Dispositive Power

12 0.00

13 Shared Dispositive Power

14 128,119.00

Aggregate amount beneficially owned by each reporting person

11 128,119.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

14 Percent of class represented by amount in Row (11)

6.7 %

Type of Reporting Person (See Instructions)

14 CO

## SCHEDULE 13D

**CUSIP No.** 097702203

1 Name of reporting person

Pivotal bioVenture Partners Fund I, L.P.

2 Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only

4 Source of funds (See Instructions)

WC

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6 Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person 7 Sole Voting Power

8 0.00

9 Shared Voting Power

78,445.00

9 Sole Dispositive Power

Person  
With: 0.00  
Shared Dispositive Power  
10  
78,445.00

11 Aggregate amount beneficially owned by each reporting person  
78,445.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13   
Percent of class represented by amount in Row (11)

14 4.1 %  
Type of Reporting Person (See Instructions)

PN

## SCHEDULE 13D

**CUSIP No.** 097702203

1 Name of reporting person  
Pivotal bioVenture Partners Fund I G.P., L.P.  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 CAYMAN ISLANDS

7 Sole Voting Power  
0.00  
Number of  
Shares Beneficially  
Owned by  
Each  
Reporting  
Person  
With: 8  
78,445.00  
9  
0.00  
10  
78,445.00  
Shared Voting Power  
Sole Dispositive Power  
Shared Dispositive Power

11 Aggregate amount beneficially owned by each reporting person  
78,445.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13   
Percent of class represented by amount in Row (11)

4.1 %  
Type of Reporting Person (See Instructions)

14

PN

## SCHEDULE 13D

**CUSIP No.** 097702203

Name of reporting person

1

Pivotal bioVenture Partners Fund I U.G.P. Ltd.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

Owned by

78,445.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

78,445.00

Aggregate amount beneficially owned by each reporting person

11

78,445.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

4.1 %

Type of Reporting Person (See Instructions)

14

CO

## SCHEDULE 13D

**CUSIP No.** 097702203

1 Name of reporting person  
Pivotal Partners Ltd  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 CAYMAN ISLANDS  
Sole Voting Power

7  
Number of Shares Beneficially Owned by Each Reporting Person With:

0.00	Sole Dispositive Power
8	Shared Dispositive Power
78,445.00	
9	0.00
10	78,445.00

11 Aggregate amount beneficially owned by each reporting person  
78,445.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 4.1 %  
Type of Reporting Person (See Instructions)

14 CO

**SCHEDULE 13D**

**CUSIP No.** 097702203

1 Name of reporting person  
Pivotal Life Sciences Holdings Limited  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization  
6 CAYMAN ISLANDS  
Sole Voting Power  
7 0.00  
Number of Shares Beneficially Owned by Each Reporting Person With: 8 Shared Voting Power  
78,445.00  
Sole Dispositive Power  
9 0.00  
Shared Dispositive Power  
10 78,445.00  
Aggregate amount beneficially owned by each reporting person  
11 78,445.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)  
12  
  
Percent of class represented by amount in Row (11)  
13 4.1 %  
Type of Reporting Person (See Instructions)  
14 CO

## SCHEDULE 13D

**CUSIP No.** 097702203

1 Name of reporting person  
Nan Fung Life Sciences Holdings Limited  
Check the appropriate box if a member of a Group (See Instructions)  
2  (a)  
 (b)  
3 SEC use only  
Source of funds (See Instructions)  
4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)  
5   
Citizenship or place of organization  
6 VIRGIN ISLANDS, BRITISH  
Number of Shares Beneficially Owned by Each Reporting Person With: 7 Sole Voting Power  
0.00  
Shared Voting Power  
8 123,119.00  
Sole Dispositive Power  
9 0.00

10 Shared Dispositive Power

123,119.00

Aggregate amount beneficially owned by each reporting person

11

123,119.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

6.4 %

Type of Reporting Person (See Instructions)

14

CO

## SCHEDULE 13D

**CUSIP No.** 097702203

Name of reporting person

1

Permwell Management Limited

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

Owned by

5,000.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

5,000.00

Aggregate amount beneficially owned by each reporting person

11

5,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.3 %

Type of Reporting Person (See Instructions)

14

CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person  
NFLS Beta Limited  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 VIRGIN ISLANDS, BRITISH  
Sole Voting Power

7 0.00  
Number of Shares Beneficially Owned by Each Reporting Person With:  
Shared Voting Power  
8 44,674.00  
Sole Dispositive Power  
9 0.00  
Shared Dispositive Power  
10 44,674.00

11 Aggregate amount beneficially owned by each reporting person  
44,674.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 2.3 %  
Type of Reporting Person (See Instructions)

14 CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person

NFLS Platform Holdings Limited

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

Owned by

44,674.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

44,674.00

Aggregate amount beneficially owned by each reporting person

11

44,674.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

2.3 %

Type of Reporting Person (See Instructions)

14

CO

## SCHEDULE 13D

### Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, \$0.00001 par value

Name of Issuer:

(b)

Bolt Biotherapeutics, Inc.

Address of Issuer's Principal Executive Offices:

(c)

900 Chesapeake Drive, Redwood City, CALIFORNIA , 94063.

### Item 5. Interest in Securities of the Issuer

Items 5(a)-(c) of the Schedule 13D are amended and restated as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 1,919,441 outstanding shares of Common Stock, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. In addition, Mr. Kam Chung Leung directly owns 8,684 shares of Common Stock.

(a)

(b)

The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

(c)

Except as set forth on Schedule A, which is incorporated into this Item 5(c) by reference, no Reporting Person has

effected any transaction in shares of Common Stock in the past sixty days.

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

### Nan Fung Group Holdings Limited

Signature: /s/ Tang Chun Wai Nelson  
Name/Title: Tang Chun Wai Nelson, Director  
Date: 02/17/2026

### NF Investment Holdings Limited

Signature: /s/ Tang Chun Wai Nelson  
Name/Title: Tang Chun Wai Nelson, Director  
Date: 02/17/2026

### Pivotal bioVenture Partners Fund I, L.P.

Signature: By Pivotal bioVenture Partners Fund I G.P., L.P.  
Name/Title: its General Partner  
Date: 02/17/2026

Signature: By Pivotal bioVenture Partners Fund I U.G.P.,  
Ltd.  
Name/Title: its General Partner  
Date: 02/17/2026

Signature: /s/ Robert Hopfner  
Name/Title: Robert Hopfner, Authorized Signatory  
Date: 02/17/2026

### Pivotal bioVenture Partners Fund I G.P., L.P.

Signature: By Pivotal bioVenture Partners Fund I U.G.P.,  
Ltd.  
Name/Title: its General Partner  
Date: 02/17/2026

Signature: /s/ Robert Hopfner  
Name/Title: Robert Hopfner, Authorized Signatory  
Date: 02/17/2026

### Pivotal bioVenture Partners Fund I U.G.P. Ltd.

Signature: /s/ Robert Hopfner  
Name/Title: Robert Hopfner, Authorized Signatory  
Date: 02/17/2026

### Pivotal Partners Ltd

Signature: /s/ Sun Xintong  
Name/Title: Sun Xintong, Director  
Date: 02/17/2026

### Pivotal Life Sciences Holdings Limited

Signature: /s/ Sun Xintong  
Name/Title: Sun Xintong, Director  
Date: 02/17/2026

### Nan Fung Life Sciences Holdings Limited

Signature: /s/ Sun Xintong  
Name/Title: Sun Xintong, Director  
Date: 02/17/2026

Permwell Management Limited

Signature: /s/ Tang Chun Wai Nelson

Name/Title: Tang Chun Wai Nelson, Director

Date: 02/17/2026

NFLS Beta Limited

Signature: /s/ Sun Xintong

Name/Title: Sun Xintong, Director

Date: 02/17/2026

NFLS Platform Holdings Limited

Signature: /s/ Sun Xintong

Name/Title: Sun Xintong, Director

Date: 02/17/2026

Schedule A

Fund	Date	Transaction	Number of shares	Price
Pivotal bioVenture Partners Fund I, L.P.	01/28/2026	Sale	3,257	\$6.8348
NFLS Beta Limited		Sale	1,343	\$6.8502
Pivotal bioVenture Partners Fund I, L.P.	01/29/2026	Sale	2,612	\$6.4524
NFLS Beta Limited		Sale	1,488	
Pivotal bioVenture Partners Fund I, L.P.	01/30/2026	Sale	1,657	\$6.1325
NFLS Beta Limited		Sale	943	
Pivotal bioVenture Partners Fund I, L.P.	02/02/2026	Sale	1,402	\$6.0495
NFLS Beta Limited		Sale	798	
Pivotal bioVenture Partners Fund I, L.P.	02/03/2026	Sale	319	\$6.0141
NFLS Beta Limited		Sale	182	
Pivotal bioVenture Partners Fund I, L.P.	02/05/2026	Sale	2,867	\$5.7272
NFLS Beta Limited		Sale	1,633	
Pivotal bioVenture Partners Fund I, L.P.	02/06/2026	Sale	1,720	\$5.58
NFLS Beta Limited		Sale	980	
Pivotal bioVenture Partners Fund I, L.P.	02/09/2026	Sale	510	\$5.5139
NFLS Beta Limited		Sale	290	
Pivotal bioVenture Partners Fund I, L.P.	02/12/2026	Sale	510	\$4.9606
NFLS Beta Limited		Sale	290	
Pivotal bioVenture Partners Fund I, L.P.	02/13/2026	Sale	1,274	\$5.0073
NFLS Beta Limited		Sale	726	